EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01257594
Recruitment Status : Active, not recruiting
First Posted : December 9, 2010
Last Update Posted : September 8, 2016
Genentech, Inc.
OSI Pharmaceuticals
Information provided by (Responsible Party):
Andrew Lassman, Columbia University

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : December 2016
  Estimated Study Completion Date : December 2016